Skip to content

Nasdaq · CIK 0001810182

ALXO ALX ONCOLOGY HOLDINGS INC

Insider trading from SEC Form 4. Last filing Oct 16, 2025. Close $1.25 on Oct 9, 2026, +16% from the 52-week low and -52% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company

Price and insider trades, last year

ALXOOct 9, 2026 · close 1.25

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at ALX ONCOLOGY HOLDINGS INC, scored.

ScoreInsiderValueHoldingsPrice contextFiled
49ModerateJason Lettmann
CHIEF EXECUTIVE OFFICER
buy
$99k
92,233 shares
+43%+166% from low-50% from high
45ModerateHarish Shantharam
Chief Financial Officer
buy
$58k
75,000 shares
-+139% from low-56% from high
33WeakJason Lettmann
CHIEF EXECUTIVE OFFICER
sell
$1,525
2,382 shares
-1%+59% from low-71% from high
23WeakShelly Pinto
SVP, FINANCE AND CAO
sell
$391
611 shares
-1%+59% from low-71% from high
15WeakShelly Pinto
SVP, FINANCE AND CAO
sell
$905
2,011 shares
-2%+9% from low-80% from high
15WeakShelly Pinto
SVP, FINANCE AND CAO
sell
$659
1,532 shares
-2%+2% from low-81% from high
40ModerateJason Lettmann
CHIEF EXECUTIVE OFFICER
sell
$2,483
2,159 shares
-1%+14% from low-46% from high
35WeakJaume Pons
PRESIDENT & CSO
sell
$1,525
1,326 shares
-0%+14% from low-46% from high
30WeakShelly Pinto
SVP, FINANCE AND CAO
sell
$633
550 shares
-1%+14% from low-46% from high
30WeakShelly Pinto
Interim CFO
sell
$3,998
2,221 shares
-2%+48% from low-19% from high
28WeakJaume Pons
PRESIDENT & CSO
sell
$17k
10,796 shares
-2%+37% from low-25% from high
30WeakShelly Pinto
Interim CFO
sell
$2,253
1,426 shares
-2%+37% from low-25% from high
31WeakRekha Hemrajani
director
buy
$46k
30,000 shares
+1000%-

Transactions

The last 38 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Oct 14, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
AGrant or award
Employee Stock Option (right to buy)derivative
+597,500$0.00$0597,500Oct 16, 2025
Oct 14, 2025Harish Shantharam
Chief Financial Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+198,750$0.00$0198,750Oct 16, 2025
Oct 14, 2025Shelly Pinto
SVP, FINANCE AND CAO
AGrant or award
Employee Stock Option (right to buy)derivative
+140,000$0.00$0140,000Oct 16, 2025
Sep 17, 2025Barbara Klencke
director
AGrant or award
Stock option (right to buy)derivative
+300,000$0.00$0300,000Sep 19, 2025
Sep 16, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
POpen-market purchase
Common Stock
+21,070$1.07$22k233,958Sep 18, 2025
Sep 17, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
POpen-market purchase
Common Stock
+71,163$1.08$77k305,121Sep 18, 2025
Aug 18, 2025Harish Shantharam
Chief Financial Officer
POpen-market purchase
Common Stock
+75,000$0.78$58k75,000Aug 20, 2025
Aug 15, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
SOpen-market sale
Common Stock
-2,382$0.64$1,525212,888Aug 19, 2025
Aug 15, 2025Shelly Pinto
SVP, FINANCE AND CAO
SOpen-market sale
Common Stock
-611$0.64$39189,198Aug 19, 2025
Aug 12, 2025Daniel J. Curran
director
AGrant or award
Stock option (right to buy)derivative
+40,400$0.00$040,400Aug 13, 2025
Jul 7, 2025Shelly Pinto
SVP, FINANCE AND CAO
SOpen-market sale
Common Stock
-2,011$0.45$90586,809Jul 8, 2025
Jun 30, 2025Shelly Pinto
SVP, FINANCE AND CAO
SOpen-market sale
Common Stock
-1,532$0.43$65988,820Jul 1, 2025
Apr 11, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
AGrant or award
Employee Stock Option (right to buy)derivative
+125,000$0.00$0125,000Apr 15, 2025
Apr 11, 2025Harish Shantharam
Chief Financial Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+125,000$0.00$0125,000Apr 15, 2025
Apr 11, 2025Alan B. Sandler
Chief Medical Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+125,000$0.00$0125,000Apr 15, 2025
Apr 11, 2025Shelly Pinto
SVP, FINANCE AND CAO
AGrant or award
Employee Stock Option (right to buy)derivative
+90,000$0.00$090,000Apr 15, 2025
Mar 14, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
AGrant or award
Common Stock
+42,000$0.00$0212,270Mar 18, 2025
Mar 14, 2025Shelly Pinto
SVP, FINANCE AND CAO
AGrant or award
Common Stock
+3,000$0.00$090,352Mar 18, 2025
Feb 19, 2025Shelly Pinto
SVP, FINANCE AND CAO
SOpen-market sale
Common Stock
-550$1.15$63387,352Feb 21, 2025
Feb 19, 2025Jaume Pons
PRESIDENT & CSO
SOpen-market sale
Common Stock
-1,326$1.15$1,525579,388Feb 21, 2025
Feb 19, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
SOpen-market sale
Common Stock
-2,159$1.15$2,483170,270Feb 21, 2025
Jan 21, 2025Jason Lettmann
CHIEF EXECUTIVE OFFICER
AGrant or award
Employee Stock Option (right to buy)derivative
+478,000$0.00$0478,000Jan 23, 2025
Jan 21, 2025Rekha Hemrajani
director
AGrant or award
Stock Option (right to buy)derivative
+40,400$0.00$040,400Jan 23, 2025
Jan 21, 2025J. Scott Garland
director
AGrant or award
Common Stockderivative
+40,400$0.00$040,400Jan 23, 2025
Jan 21, 2025Corey S Goodman
director, owner
AGrant or award
Stock Option (right to buy)derivative
+40,400$0.00$040,400Jan 23, 2025
Jan 21, 2025Chris H Takimoto
director
AGrant or award
Common Stock (right to buy)derivative
+40,400$0.00$040,400Jan 23, 2025
Jan 21, 2025Barbara Klencke
director
AGrant or award
Stock Option (right to buy)derivative
+40,400$0.00$040,400Jan 23, 2025
Jan 21, 2025Harish Shantharam
Chief Financial Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+600,000$0.00$0600,000Jan 23, 2025
Jan 21, 2025Shelly Pinto
SVP, FINANCE AND CAO
AGrant or award
Employee Stock Option (right to buy)derivative
+112,000$0.00$0112,000Jan 23, 2025
Jan 21, 2025Alan B. Sandler
Chief Medical Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+100,000$0.00$0100,000Jan 23, 2025
Jan 21, 2025Jaume Pons
PRESIDENT & CSO
AGrant or award
Employee Stock Option (right to buy)derivative
+50,000$0.00$050,000Jan 23, 2025
Jan 6, 2025Shelly Pinto
Interim CFO
SOpen-market sale
Common Stock
-2,221$1.80$3,99887,902Jan 8, 2025
Dec 30, 2024Jaume Pons
PRESIDENT & CSO
SOpen-market sale
Common Stock
-10,796$1.58$17k580,714Jan 2, 2025
Dec 30, 2024Shelly Pinto
Interim CFO
SOpen-market sale
Common Stock
-1,426$1.58$2,25390,123Jan 2, 2025
Dec 2, 2024Jason Lettmann
CHIEF EXECUTIVE OFFICER
AGrant or award
Employee Stock Option (right to buy)derivative
+200,000$0.00$0200,000Dec 4, 2024
Dec 2, 2024Shelly Pinto
Interim CFO
AGrant or award
Employee Stock Option (right to buy)derivative
+150,000$0.00$0150,000Dec 4, 2024
Dec 2, 2024Rekha Hemrajani
director
POpen-market purchase
Common Stock
+30,000$1.55$46k33,000Dec 4, 2024
Nov 18, 2024Alan B. Sandler
Chief Medical Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+600,000$0.00$0600,000Nov 19, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

ALXO insider trading: ALX ONCOLOGY HOLDINGS INC | InsiderTell